08/16/2022 | Press release | Distributed by Public on 08/16/2022 04:14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
☐
|
Transition Report on Form 10-K
|
☐
|
Transition Report on Form 20-F
|
☐
|
Transition Report on Form 11-K
|
☐
|
Transition Report on Form 10-Q
|
☐
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed date; and
|
☐
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
Shimon Citron
|
+972
|
546611525
|
|||
(Name)
|
(Area Code)
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
Yes ☒ No ☐
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
Yes ☒ No ☐
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
|
The registrant expects that its revenues will be materially increased compared to its prior quarterly report on Form 10-Q for the period ended March 31, 2022, due to the acquisition of Manuka Ltd. which was acquired on June 30, 2022.
|
Artemis Therapeutics, Inc.
|
||
(Name of Registrant as Specified in Charter)
|
Date:
|
August 15, 2022
|
By:
|
/s/ Shimon Citron
|
|
Name: Shimon Citron
|
||||
(Title): Chief Executive Officer
|
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)
|